Trials 42
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-06-16 | Chong Kun Dang Pharmaceutical | Results 종근당, 듀비에 혈당강하 효과•SGLT-2i 병용요법에 대한 연구 발표 ckdpharm.com ↗
종근당 ( 대표 김영주 ) 은 최근 부산 롯데호텔에서 개최된 ‘2023 대한내분비학회 춘계학술대회 심포지엄 ’ 에서 당뇨병치료제 ‘ 듀비에 ’ 의 혈당강하 효과와 SGLT-2 억제제 병용 요법에 대한 연구 결과를 발표했다고 21 일 밝혔다 . |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-06-16 | Chong Kun Dang Pharmaceutical | 종근당, 듀비에 혈당강하 효과•SGLT-2i 병용요법에 대한 연구 발표 ckdpharm.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 46 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lobeglitazone | “This is a Phase 1, single-center, parallel group study designed to determine the single-dose safety and PK profile of lobeglitazone from M107 ODT and Duvie, both administered...” NCT07056517 ↗17“PURPOSE: Lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, is metabolized primarily by the cytochrome P450 (CYP) 3A4 isoenzyme.” PMID 25047497 ↗ Jul 2014 “An Assessment of Pharmacokinetic Interaction Between Lobeglitazone and Sitagliptin After Multiple Oral Administrations in Healthy Men.” PMID 32362346 ↗ Apr 2020 “0.25 or 0.5 mg Duvie (Lobeglitazone) in Patients With Type 2 Diabetes With Inadequate Control on Metformin and DPP-4 Inhibitor Therapy” NCT03770052 ↗ “Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg” NCT04869800 ↗ “Efficacy and Safety of Lobeglitazone Versus Sitagliptin” NCT02480465 ↗ “metformin+sitagliptin (Januvia)+lobeglitazone (Duvie)” NCT02188186 ↗ “Lobeglitazone Sulfate 0.5mg, Metformin HCl 1000mg” NCT02565368 ↗ “1. D308 2. CKD-501: Lobeglitazone sulfate 0.5mg” NCT03616392 ↗ “Lobeglitazone, Empagliflozin, Metformin” NCT06492655 ↗ |
| Known as | CKD-501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04810676 ↗ |
| Known as | CKD-501 : Lobeglitazone | “CKD-501 : Lobeglitazone” NCT01133431 ↗ |
| Known as | Duvie | “0.25 or 0.5 mg Duvie (Lobeglitazone) in Patients With Type 2 Diabetes With Inadequate Control on Metformin and DPP-4 Inhibitor Therapy” NCT03770052 ↗2“we investigated the hepatic effects of the novel thiazolidinedione (TZDs), lobeglitazone (Duvie) in T2D patients with NAFLD.” PMID 27914133 ↗ Jan 2017 “metformin+sitagliptin (Januvia)+lobeglitazone (Duvie)” NCT02188186 ↗ |
| Known as | Lobeglitazona | ChEMBL registry synonym — accepted as the source's own label CHEMBL3585580 ↗ |
| Known as | lobeglitazone sulfate | “1 tablet of lobeglitazone sulfate (0.5 mg) once daily for 5 days” PMID 32362346 ↗ Apr 20202“Lobeglitazone Sulfate 0.5mg, Metformin HCl 1500mg” NCT02627027 ↗ “1. D308 2. CKD-501: Lobeglitazone sulfate 0.5mg” NCT03616392 ↗ |
| Action | Activate | “CKD-501 is highly selective peroxisome proliferator-activated receptor-gamma agonist” NCT01001611 ↗ |
| Modality | Small molecule | “Lobeglitazone, a Novel Thiazolidinedione” PMID 27914133 ↗ Jan 2017 |
| Route | Oral | “0.5 mg/tablet, orally, 1 tablet once daily for 24 weeks or 52 weeks (If extension study)” NCT01001611 ↗ |
| Target | PPARG | “Lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist” PMID 25047497 ↗ Jul 2014 |